Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors with Obesity and Muscle Weakness

Recruiting

Phase 2

Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors with Obesity and Muscle WeaknessSafety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors with Obesity and Muscle Weakness

Sponsor:

Immunis, Inc.

Code:

NCT06600581

Conditions

Muscle Performance

Sarcopenic Obesity

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Not accepted

Interventions

IMM01-STEM

Placebo

IMM01-STEM alternating with placebo (saline)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by Immunis, Inc. on 2025-03-25.